Medicsight buy

“The medical imaging software specialist Medicsight has received approval from the Chinese State Food and Drug Administration (SFDA) for its MedicRead Colon workstation.” (10 Apr, Investors Chronicle)

Leading to IC recommendation:

“Shares in Medicsight have slipped since we advised buying (70.5p, 7 March 2008) the turn of the year. But, with success pegged to the group securing approvals [“The forthcoming year will be extremely important for Medicsight with the expected clearance from the US Food & Drug Administration (FDA) and the Japanese Ministry of Health Labour and Welfare (MHLW), which will unlock significant revenue,’ said chief executive David Sumner”], recovery should be on the cards and, at 59p, the shares remain a buy.”

Hmm, sounds interesting. See CEO David Sumner explain more on TV in an interview at CNBC on 18 February following the Toshiba partnership. A few points copied from IC, with addition from me in red:


Operating in world’s largest health markets

Added market intel from sister company Medicexchange

Expanding list of partnerships, eg Visage Imaging

Approvals for Japan and US entry due

Global increase in CT imaging and regulatory impetus


Future growth dependent on regulatory approvals

Loss making